---
title: "Guardant Health, Inc. (GH.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/GH.US.md"
symbol: "GH.US"
name: "Guardant Health, Inc."
industry: "Health Care Services"
datetime: "2026-05-19T23:07:25.983Z"
locales:
  - [en](https://longbridge.com/en/quote/GH.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/GH.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/GH.US.md)
---

# Guardant Health, Inc. (GH.US)

## Company Overview

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies.

| Item | Detail |
|------|--------|
| Industry | Health Care Services |
| Exchange | US Market |
| Website | [guardanthealth.com](https://guardanthealth.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: C (0.41)**

**Industry**: Health Care Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 33 / 87 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 39.56% |  |
| Net Profit YoY | -4.00% |  |
| P/B Ratio | -69.30 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 12547764386.06 |  |
| Revenue | 1080215000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 200.62% | A |
| Profit Margin | -40.10% | E |
| Gross Margin | 65.22% | A |
| Revenue YoY | 39.56% | A |
| Net Profit YoY | -4.00% | C |
| Total Assets YoY | 42.48% | A |
| Net Assets YoY | 27.80% | A |
| Cash Flow Margin | 43.33% | C |
| OCF YoY | 39.56% | A |
| Turnover | 0.66 | B |
| Gearing Ratio | 109.45% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Guardant Health, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "39.56%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-4.00%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-69.30",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "12547764386.06",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1080215000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "200.62%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-40.10%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "65.22%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "39.56%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-4.00%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "42.48%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "27.80%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "43.33%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "39.56%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.66",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "109.45%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -28.97 | 56/87 | - | - | - |
| PB | -69.30 | 67/87 | - | - | - |
| PS (TTM) | 11.62 | 65/87 | 14.56 | 11.29 | 8.09 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cigna (CI.US) | B | C | A | D | B | B |
| 02 | BrightSpring Health Services - Unit (BTSGU.US) | C | A | A | D | B | B |
| 03 | Fresenius (FSNUY.US) | C | B | C | C | B | B |
| 04 | Quest Diagnostics (DGX.US) | B | B | B | C | B | B |
| 05 | Labcorp (LH.US) | B | B | B | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **23**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 16 | 70% |
| Overweight | 4 | 17% |
| Hold | 2 | 9% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 98.19 |
| Highest Target | 180.00 |
| Lowest Target | 90.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/GH.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/GH.US/norm.md)
- [Related News](https://longbridge.com/en/quote/GH.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/GH.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**